Gt biopharma reports third quarter 2023 financial results

Brisbane, california, nov. 01, 2023 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced third quarter 2023 results for the period ended september 30, 2023.
GTBP Ratings Summary
GTBP Quant Ranking